BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://www.bricbordeaux.com/en/ X-WR-CALDESC:Events for Bordeaux Institute of Oncology REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Paris BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20260329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20261025T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20250319 DTEND;VALUE=DATE:20250322 DTSTAMP:20241219T151854Z CREATED:20241219T151854Z LAST-MODIFIED:20241219T151854Z UID:48530-1742342400-1742601599@www.bricbordeaux.com SUMMARY:Annual Congress of the French Society for Gene and Cell Therapy (SFTCG) DESCRIPTION:Annual congress of the French Society for Gene and Cell Therapy (SFTCG)\, organized by François Moreau-Gaudry (team 8\, Biotherapies Génétique et Oncologie -BioGO).\n\n \n \n March 19 to 21\, 2025\n \n Agora du Haut Carré\, Talence. \n \n Free registration for students submitting an abstract\n \n \n \n https://www.sftcg.fr/annual-congress URL:https://www.bricbordeaux.com/en/event/annual-congress-of-the-french-society-for-gene-and-cell-therapy-sftcg/ LOCATION:Agora du Haut Carré – Université de Bordeaux\, 43 rue Pierre Noailles\, Talence\, France CATEGORIES:Meetings ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2024/12/colloque-sftcg-2025-03-2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250403T120000 DTEND;TZID=Europe/Paris:20250403T130000 DTSTAMP:20250401T100244Z CREATED:20250331T154329Z LAST-MODIFIED:20250401T100244Z UID:49016-1743681600-1743685200@www.bricbordeaux.com SUMMARY:Leica - Seminar and demonstration of the Confocal Stellaris microscope DESCRIPTION:LEICA will be at BBS on April 2 and 3\, 2025\, to demonstrate the Confocal Stellaris microscope.\n\n\nClément Laigle\, LEICA Applications Engineer\, will present the various acquisition options at a unit seminar on Thursday April 3\, from 12 noon to 1 pm.\nTo register\, see email sent by Walid Mahfouf on 26/03. If you are not from BRIC\, contact walid.mahfouf@u-bordeaux.fr \nDemo sessions last from 1h to 1h30 and are open to 3 people. You can reserve your slots on the ENT reservation site in the “BBS4-Demo Stellaris” resource family. \n\nLeica contact:\nAndy Tempez\nProduct Specialist Confocal Microscopy\nFrance South\nandy.tempez@leica-microsystems.com\nMobile : +33 6 74 40 34 72 URL:https://www.bricbordeaux.com/en/event/leica-seminar-and-demonstration-of-the-confocal-stellaris-microscope/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/leica-seminaire-avril-2025-bric.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250403T140000 DTEND;TZID=Europe/Paris:20250404T120000 DTSTAMP:20250407T122608Z CREATED:20250320T165759Z LAST-MODIFIED:20250407T122608Z UID:48992-1743688800-1743768000@www.bricbordeaux.com SUMMARY:Innovation in oncology DESCRIPTION:Your research could open up new perspectives!\nTechnology transfer is the key to innovation in oncology\, because it brings research advances to patients. How can we transform these scientific discoveries into concrete solutions for patients and society? How can we support you in this process? \nTo answer these questions\, SATT Aquitaine\, Inserm-Transfert and the BRIC laboratory are organizing an information and exchange session on April 3 and 4\, 2025\, to explore the opportunities for commercialization and better understand the support mechanisms available. \nThis event is aimed at researchers\, engineers and doctoral students who want to find out more about how to get the most out of their work and the opportunities available to them. A unique opportunity to meet and exchange with technology transfer experts and explore new perspectives for your research. \n \nInformation and contact: \nAndréa Le Brazidec : a.lebrazidec@ast-innovations.com \n\nMore details and registration at this link.\n———————–\nProgram\nThursday\, April 03 – 2pm-5pm: Understand and be inspired!\nLocation: Amphi Centre Broca Nouvelle – Aquitaine – RdC14h00 – Introduction with Frédéric Saltel\, Director of BRIC. \n14h10 – Feedback\nGrégoire Prevost\, entrepreneur in residence at the BRIC Lab\, will highlight the challenges and opportunities of technology transfer identified during his mission. \n\nWhat obstacles have been identified to technology transfer in the lab?\nWhy and how can you add value to your work?\nWhat are the opportunities for oncology research?\n\n15h00 – Innovation support schemes \nSATT Aquitaine and Inserm Transfert will be presenting their support services for researchers. \n\nHow can SATT Aquitaine and Inserm Transfert help you?\nWhat is the relationship between SATT Aquitaine and Inserm Transfert?\nWhat business model for technology transfer?\nA few examples of value-adding in the healthcare sector.\n\n15h50 – The concrete case of a BRIC start-up\nBy Madeleine Moscatelli CEO of BeLiver. \n16h10 – The OncoSTART consortium \nLucia Robert\, coordinator of OncoSTART and CEO of MATWIN\, will present this program dedicated to researchers wishing to enter the field of oncology. \n16h30 – Informal exchange over a snack \n\nFriday\, April 04 – 09h-12h: Taking action!\nLocation: Meeting room S.2040 Est (BBS – Salles R+2)\, on registration09h00 – Workshops: Structuring your oncology project\nTake advantage of Grégoire Prevost’s expertise to work on the positioning and value of your research results\, analyze its strengths\, weaknesses\, opportunities and threats\, and start building a structured action plan. \n\nEvaluate your project with a strategic SWOT analysis.\nDetermine your invention’s Target Product Profile\, used to describe the ideal characteristics of a product prior to development.\nDesign your roadmap to define the steps and milestones you need to reach to bring your project to fruition. URL:https://www.bricbordeaux.com/en/event/innovation-in-oncology/ CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/journee-de-formation-a-la-valorisation--pui-bordeaux-bric-avril-2025.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250415T140000 DTEND;TZID=Europe/Paris:20250415T170000 DTSTAMP:20250317T161408Z CREATED:20250317T154528Z LAST-MODIFIED:20250317T161408Z UID:48931-1744725600-1744736400@www.bricbordeaux.com SUMMARY:Thesis defense Marine JAUVAIN\, team 4 DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.” URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jouvain-team-4/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250415T140000 DTEND;TZID=Europe/Paris:20250415T170000 DTSTAMP:20250331T133552Z CREATED:20250317T161656Z LAST-MODIFIED:20250331T133552Z UID:48937-1744725600-1744736400@www.bricbordeaux.com SUMMARY:Thesis defense Marine JAUVAIN\, team 4 DESCRIPTION:Defense of thesis in Microbiology – Immunology \nMarine JAUVAIN\, University hospital assistant\nTeam 04 – Helicobacter-associated digestive cancers\, cancer stem cells and therapeutic strategies.\nThesis supervision Émilie BESSEDE \nTuesday\, April 15 – 2pm Amphi BBS (Bordeaux Biologie Santé) site Carreire Université de Bordeaux – 2 rue du Dr Hoffmann Martinot – Bordeaux \n“Étude du microenvironnement bactérien dans le contexte de la carcinogenèse gastrique.” \nSummary and notice of defense available at this link URL:https://www.bricbordeaux.com/en/event/thesis-defense-marine-jauvain-team-4/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/03/soutenance-de-these-marine-jauvain-team-4.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250418T110000 DTEND;TZID=Europe/Paris:20250418T120000 DTSTAMP:20250415T075049Z CREATED:20250414T093133Z LAST-MODIFIED:20250415T075049Z UID:49146-1744974000-1744977600@www.bricbordeaux.com SUMMARY:Invited seminar Léa Lemaitre - 18-04-2025 DESCRIPTION:Dr Léa Lemaitre \nPost Doc\, Division of Gastroenterology and Hepatology\, Stanford University\, Stanford\, CA\, USA \ninvited by Christophe Grosset\, team 6 MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nTitle: Targeting Macrophage-Mediated Mechanisms of Immune Evasion as adjuvant therapy in TACE-resistant Hepatocellular Carcinoma. \n  \nAbstract: \nA key obstacle to progress in treatment of hepatocellular carcinoma (HCC) is the notorious tenacity of HCC to recur. Transarterial chemoembolization (TACE) is the most common treatment for unresectable HCC\, however\, it fails to provide a durable cure. The crux of the problem lies in residual cancer cells that persist after TACE. Our goal is to understand how these residual cells escape immune detection and survive after TACE in order to develop effective adjuvant therapies. \nWe used both in vitro and in vivo methods to mimic TACE- resistance by generating doxorubicin resistant- residual HCC models. We performed single-cell RNA sequencing on 3D tumoroids (31\,000 cells) of doxorubicin resistant vs control HCC in coculture with macrophages. In addition\, HCC patient-derived tumor cells and macrophages were used for validation. We developed an immunocompetent mouse model of syngeneic orthotopic allograft model of HCC\, using doxorubicin-resistant or control HCC cell lines to test adjuvant therapies. \nUsing scRNAseq of 3D tumoroid model\, we show that doxorubicin-resistant cancer cells exhibit a stem-cell-like phenotype with high expression of stemness markers (CK19\, CD44)\, TGFb pathway (TGFBR1) and cytokines driving pro- tumor macrophage polarization (CXCL8\, CCL2). On the other hand\, the macrophages co-cultured with doxorubicin-resistant HCC showed a pro-tumor phenotype with increased PDL1 expression. We validated this finding using patient-derived samples\, showing that doxorubicin resistant HCC tumoroid co- culture increased PDL1 expression on macrophages. Further\, mRNA FISH showed that the CD68+ macrophages expressed higher levels of TGFB1 in TACE-resistant HCC than primary HCC (p=0.0011). Based on our in vitro analysis we identified the TGFB pathway and PDL1 as potential synergistic targets for adjuvant therapy of TACE-resistant HCC. In our mouse model of doxorubicin-resistant orthotopic allografts\, we showed that treatment with combined TgfbrI and anti-Pdl1 antibodies resulted in significantly reduced liver tumor burden (p=0.01). Flow cytometry analysis revealed immune remodeling with increased infiltration of CD8T cells and M1-like macrophage (CD86+/MHC- II+)\, along with depletion of macrophages (PDL1+/CD206+) in the liver of treated doxorubicin-resistant orthotopic allografts. \nWe generated in vitro 3D models of TACE-resistance in HCC and identified the mechanistic roles of the PDL1+ macrophage-derived TGFβ1 on stem-like cancer cell persistence. We developed a mouse model of doxorubicin-resistant HCC and demonstrated that combined targeting of Pdl1 and Tgfb1 blocks tumor progression and evokes and anti-tumor macrophage and CD8T cell immune response. Thus combined targeting of PDL1 and TGFB1 holds therapeutic potential as adjuvant therapy in TACE to eliminate residual HCC\, reduce recurrence and improve patient outcomes in HCC. \n  \nBiosketch: \nMy long-term research goals are to improve immunotherapies for cancer treatment. My objective is to decipher the complexity of the immune system in the tumor microenvironment. My academic training as a pharmacist and research scientist provides me with a strong background in pharmacy\, medicine\, clinical research\, immunology\, and oncology. \nIn my first year of pharmacy residency\, I was involved in clinical trials\, and I developed a novel chromatographic method to detect errors in the administration of intravenous chemotherapy. During my residency\, I developed a strong interest in oncology research leading me to pursue an integrated masters program under the mentorship of Dr. Bettina Couderc. I analyzed the crosstalk between macrophages and mesenchymal stromal cells (MSCs) in chemotherapy-resistant ovarian cancer leading to 3 co-author publications. This research project reinforced my passion for immune-oncology. To further understand the role of MSCs in cancer resistance to therapies\, I pursued PhD training under the supervision of Dr. Bettina Couderc and Jill Corre\, entitled “Phenotypic and functional characterization of cancer-associated MSCs in multiple myeloma”. This work advanced the understanding of the tumor microenvironment in multiple myeloma and led to the publication of two first-authored publications (1\, 2). During my doctoral and postdoctoral training\, I was also involved in another project to decipher mechanisms of resistance to immunotherapy\, the results were published in Immunity with me as the second author (3). I thus gained strong training and expertise in tumor immunology and novel immune monitoring technologies. \nThree years ago\, I joined the Dhanasekaran Lab to deepen my expertise in immuno-oncology. I have gained proficiency in advanced technologies such as CyTOF\, spatial immunology and organoids. I have published a manuscript discussing macrophage-mediated mechanisms of resistance to immune checkpoint inhibitors (4\, co-author\, Cancer Res\, 2023) and an article identifying novel mechanisms of resistance to therapy in liver cancer (5\, first author\, Nat Cancer\, 2024). These papers serve as a cornerstone for my current application to develop a precision oncology platform for immunotherapy in HCC. Alongside my mentor\, I have crafted a comprehensive career development plan aimed at enhancing my abilities in grant writing\, mentoring\, teaching\, and communication. \n  \n\nLea Lemaitre\, DoSouto Ferreira L\, Joubert MV\, Avet-Loiseau H\, Martinet L\, Corre J\, Couderc Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma. Int J Mol Sci. 2020 May 28. \nLea Lemaitre\, Hamaidia M\, Descamps JG\, Do Souto Ferreira L\, Joubert MV\, Gadelorge M\, Avet-Loiseau H\, Justo A\, Reina N\, Deschaseaux F\, Martinet L\, Bourin P\, Corre J\, Espagnolle N. Toll-like receptor 4 selective inhibition in medullary microenvironment alters multiple myeloma cell growth. Blood advance. 2022 Jan 25; 6(2):672-678. \nWeulersse M*\, Asrir A*\, Pichler AC*\, Lemaitre Lea\, Braun M\, Carrié N\, Joubert MV\, Le Moine M\, Do Souto L\, Gaud G\, Das I\, Brauns E\, Scarlata CM\, Morandi E\, Sundarrajan A\, Cuisinier M\, Buisson L\, Maheo S\, Kassem S\, Agesta A\, Pérès M\, Verhoeyen E\, Martinez A\, Mazieres J\, Dupré L\, Gossye T\, Pancaldi V\, Guillerey C\, Ayyoub M\, Dejean AS\, Saoudi A\, Goriely S\, Avet-Loiseau H\, Bald T\, Smyth MJ\, Martinet L.. ** co-authors. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8 + T Cell Anti- tumor Functions and Limits the Efficacy of Cancer Immunotherapy. Immunity. 2020 Oct 13.\nRenumathy Dhanasekaran\, Aida Hansen\, Jangho Park\, Lea Lemaitre\, Nia Adeniji\, Sibu Kuruvilla\, Akanksha Suresh\, Josephine Zhang\, Varsha Swamy\, Dean W. Felsher. MYC overexpression drives immune evasion in hepatocellular carcinoma (HCC) that is reversible through restoration of pro- inflammatory macrophages. Cancer research. 2022 Dec 16. \nLea Lemaitre*\, Nia Adeniji*\, Akanksha Suresh*\, Reshma Reguram\, Josephine Zhang\, Jangho Park\, Amit Reddy\, Alexandro E. Trevino\, Aaron T. Mayer\, Anja Deutzmann\, Aida Hansen\, Ling Tong\, Vinodhini Arjunan\, Neeraja Kambham\, Brendan Visser\, Monica Dua\, Andrew Bonham\, Nishita Kothary\, H. Blaize D’Angio\, Ryan Preska\, Yanay Rosen\, James Zou\, Vivek Charu\, Dean W. Felsher and Renumathy Dhanasekaran. Spatial Analysis Reveals Targetable Macrophage-Mediated Mechanisms of Immune Evasion in Hepatocellular Carcinoma Minimal Residual Disease. Nature cancer. 2024 Sept 20 URL:https://www.bricbordeaux.com/en/event/invited-seminar-lea-lemaitre-18-04-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-lea-lemaitre-2025-04-18.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250513T093000 DTEND;TZID=Europe/Paris:20250513T103000 DTSTAMP:20250428T132916Z CREATED:20250422T144410Z LAST-MODIFIED:20250428T132916Z UID:49188-1747128600-1747132200@www.bricbordeaux.com SUMMARY:Invited Seminar Bruno Segui -13-05-2025 DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma. \n  \nBruno Ségui \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie. \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press). \n  URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-12-05-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250513T093000 DTEND;TZID=Europe/Paris:20250513T103000 DTSTAMP:20250428T133528Z CREATED:20250428T133528Z LAST-MODIFIED:20250428T133528Z UID:49259-1747128600-1747132200@www.bricbordeaux.com SUMMARY:Invited Seminar - Bruno Segui - 13-05-2025 DESCRIPTION:Pr. Bruno Segui \, invited by Majid Khatib\, team 2 Reprograming tumor activitY and associaTed MicroenvironmEnt (Rytme).\nCo-head of the team MELASPHINX: Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy in the Toulouse Cancer Research Center (CRCT) \nTitle : TNF blockade with certolizumab\, but not infliximab\, improves efficacy of anti-PD-1 and anti-CTLA-4 combination in melanoma \n  \nAbstract \nThe combination of anti-PD-1 and anti-CTLA-4 boosts the anti-cancer immune response in patients with advanced melanoma. However\, 60% of patients fail to respond or relapse early after induction\, and 95% develop immune-related adverse events (irAEs) such as colitis\, which can be treated with infliximab\, a tumour necrosis factor-alpha inhibitor (TNFi). The impact of TNFi on immune and clinical responses remains to be elucidated. Here we provide evidence that TNF blockade can improve the response to the anti-PD-1 and anti-CTLA-4 combination not only in mice but also in patients enrolled in a phase 1b clinical trial (TICIMEL\, NTC03293784). However\, certolizumab\, but not infliximab\, strongly stimulates immune and therapeutic responses to ICI. Mechanistically\, we have shown that the IgG1 Fc fragment of infliximab impairs the ability of TNF blockade to stimulate the efficacy of ICI therapy. When combined with ICI\, certolizumab decreased the proportion of regulatory T cells (Tregs) and exhausted T cells\, while increasing the proportion of effector T cells in tumors as assessed by single-cell RNA sequencing and spectral flow cytometry. In conclusion\, our study shows that TNF impairs the immune response to melanoma and that the type of TNFi must be well selected to improve the efficacy of ICI in melanoma. \n  \n📆 Tuesday\, May 13 9:30 a.m.\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \n  \nBruno Ségui \nCV overview: \n2000: PhD in human pathophysiology (Toulouse University). \n2000-2002: Postdoctoral position (University College London\, UK). \n2006: HDR (Toulouse University). \n2002-2011: Assistant Professor of Immunology\, Faculty of Pharmacy (Toulouse III). \nSince 2011: Professor of Cell Biology\, Faculty of Pharmacy (Toulouse III). \nResearch activity in the Cancer Research Center of Toulouse (CRCT). \nSince 2019: Deputy Director of the CARe graduate school on Cancer Aging and Rejuvenation. \nSince 2021: Team leader of MELASPHINX at the Cancer Research Center of Toulouse\, \nco-PI: Dr. N. Andrieu-Abadie. \n  \nOverview of research activities: \nOver the last 25 years\, I have been studying the signalling pathways triggered by some members of the TNF receptor superfamily\, including CD40\, Fas/CD95 and TNFR1/CD120a. In this context\, we have highlighted the role of sphingolipids in the modulation of both apoptosis and immune responses (Ségui et al.\, J. Biol. Chem.\, 1999; Ségui et al\, J. Clin. Invest. 2001; Montfort et al.\, J. Immunol. 2009; Lafont et al.\, Cell Death Differ. 2010). More recently\, we have shown that TNF blockade enhances the CD8 T cell-dependent immune response (Bertrand et al.\, Cancer Res. 2015) and overcomes the resistance to anti-PD-1 (Bertrand et al.\, Nat. Commun. 2017) in mouse melanoma models. Mechanistically\, TNF triggers the activation-induced cell death of CD8+ tumour-infiltrating lymphocytes. We have translated our concept into the clinic in advanced melanoma patients\, where we have shown that two triple therapies combining TNF blockers (infliximab or certolizumab) with anti-PD-1 (nivolumab) and anti-CTLA-4 (certolizumab) are safe for patients\, with promising signs of efficacy in the certolizumab cohort (Montfort et al.\, Clin. Cancer Res 2021). Moreover\, Elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcome in patients with advanced melanoma\, reinforcing the notion that TNF may dampen the efficacy of immune checkpoint inhibitors (Virazels et al.\, Int J Cancer\, in press). \n  URL:https://www.bricbordeaux.com/en/event/invited-seminar-bruno-segui-13-05-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/seminar-bruno-segui-2025-05-13.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250514T150000 DTEND;TZID=Europe/Paris:20250514T160000 DTSTAMP:20250428T092433Z CREATED:20250428T092433Z LAST-MODIFIED:20250428T092433Z UID:49248-1747234800-1747238400@www.bricbordeaux.com SUMMARY:Invited seminar - Thomas Bertero - 14-05-2025 DESCRIPTION:Invited seminar by Violaine Moreau\, Team 3\, Liver Cancers and Tumor Invasion and Isabelle Sagot\, Quiessence and Multicellularity Team\, IBGC \nThomas Bertero is CRCN CNRS\, CNRS Bronze Medal 2019. He studies the link between the mechanical response of cells to their environment and metabolism.\nInstitut de Pharmacologie moléculaire et cellulaire (IPMC)\nUniversité Côte d’Azur/CNRS/Inserm\nValbonne \nTitle: Mechano-metabolism: From tissues to molecules\n\nAbstract :\nThe spatiotemporal control of cell behaviour requires the transmission of information from the complex structure of tissues to their constituent cells. Mechanotransduction enables this transmission by sensing mechanical environments and adapting cellular behaviours. However\, this process requires energy. Since our pioneering study demonstrating a link between cell mechanics and cell metabolism (Bertero et al\, J Clin Invest 2016) our laboratory has been interested in deciphering how tissue mechanical properties shape – and are shaped by – cell metabolism. Here\, I will summarise our recent discoveries on how the mechanical properties of the tumour niche reprogram glutamine and glucose metabolism to promote breast cancer progression. \n📆 Wednesday\, May 14\, 3pm\n📌 Amphi BBS (Bordeaux Biologie Santé) 2 rue du Dr Hoffmann Martinot \nSelected publications:\nMechano-dependent sorbitol accumulation supports biomolecular condensate. \nTorrino S\, Oldham WM\, Tejedor AR\, Burgos IS\, Nasr L\, Rachedi N\, Fraissard K\, Chauvet C\, Sbai C\, O’Hara BP\, Abélanet S\, Brau F\, Favard C\, Clavel S\, Collepardo-Guevara R\, Espinosa JR\, Ben-Sahra I\, Bertero T. Cell. 2025 Jan 23;188(2):447-464.e20. doi: 10.1016/j.cell.2024.10.048. \n\n \nSystems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. \nBertero T\, Lu Y\, Annis S\, Hale A\, Bhat B\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Vargas SO\, Graham BB\, Kumar R\, Black SM\, Fratz S\, Fineman JR\, West JD\, Haley KJ\, Waxman AB\, Chau BN\, Cottrill KA\, Chan SY. J Clin Invest. 2022 May 16;132(10):e161077. doi: 10.1172/JCI161077. \n\n \n\n\nMetabo-reciprocity in cell mechanics: feeling the demands/feeding the demand. \nTorrino S\, Bertero T. Trends Cell Biol. 2022 Jul;32(7):624-636. doi: 10.1016/j.tcb.2022.01.013. Epub 2022 Feb 14. \n \nMechano-induced cell metabolism promotes microtubule glutamylation to force metastasis. \nTorrino S\, Grasset EM\, Audebert S\, Belhadj I\, Lacoux C\, Haynes M\, Pisano S\, Abélanet S\, Brau F\, Chan SY\, Mari B\, Oldham WM\, Ewald AJ\, Bertero T. Cell Metab. 2021 Jul 6;33(7):1342-1357.e10. doi: 10.1016/j.cmet.2021.05.009. \n \n\n\nTumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy. \nBertero T\, Oldham WM\, Grasset EM\, Bourget I\, Boulter E\, Pisano S\, Hofman P\, Bellvert F\, Meneguzzi G\, Bulavin DV\, Estrach S\, Feral CC\, Chan SY\, Bozec A\, Gaggioli C. Cell Metab. 2019 Jan 8;29(1):124-140.e10. doi: 10.1016/j.cmet.2018.09.012. \n \nVascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. \nBertero T\, Oldham WM\, Cottrill KA\, Pisano S\, Vanderpool RR\, Yu Q\, Zhao J\, Tai Y\, Tang Y\, Zhang YY\, Rehman S\, Sugahara M\, Qi Z\, Gorcsan J 3rd\, Vargas SO\, Saggar R\, Saggar R\, Wallace WD\, Ross DJ\, Haley KJ\, Waxman AB\, Parikh VN\, De Marco T\, Hsue PY\, Morris A\, Simon MA\, Norris KA\, Gaggioli C\, Loscalzo J\, Fessel J\, Chan SY. J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/JCI86387. URL:https://www.bricbordeaux.com/en/event/invited-seminar-thomas-bertero-14-05-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/thomas-bertero-2025-05-14.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250517T100000 DTEND;TZID=Europe/Paris:20250517T163000 DTSTAMP:20250612T092854Z CREATED:20250512T092937Z LAST-MODIFIED:20250612T092854Z UID:49521-1747476000-1747499400@www.bricbordeaux.com SUMMARY:2025 Brain Cancer Open House Day DESCRIPTION:As part of Brain Cancer Awareness Month\, the BRIC is once again organizing its Open House Day on Saturday\, May 17\, 2025\, from 10:00 AM to 4:30 PM\, at its facilities located in Pessac\, on the François Bordes campus (Building B2). \nThis initiative\, fully aligned with the goal of science outreach\, aims to introduce the general public to the daily life of researchers and recent advances in brain cancer research — through engaging\, accessible formats. \nThis free event\, open to everyone\, will feature:\nGuided tours of part of the BRIC’s research labs\nInformation stations with simplified posters\, presented by researchers from Team 1\nMini-seminars\nDiscussions with scientists\, healthcare professionals\, and patient advocacy groups\, including: \nParticipating associations:La Ligue contre le cancer\, Des Étoiles dans la Mer\, ARTC (Association for Brain Tumor Research)\, and ADAM (Association for Children with Medulloblastoma). \nThis initiative is led by Team 1 of the BRIC\, in collaboration with its institutional sponsors (Inserm\, University of Bordeaux\, CNRS) and scientific partners (IBGC and GBMetabo). \n📍 Access: Tram B (François Bordes or Doyen Brus stops) – Free parking nearby (Avenue Léon Duguit\, Pessac) URL:https://www.bricbordeaux.com/en/event/2025-brain-cancer-open-house-day/ LOCATION:Bâtiment B2\, Allée Geoffroy Saint-Hilaire\, PESSAC\, 33600\, France CATEGORIES:Meetings ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/portes-ouvertes-17-mai.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250612T101500 DTEND;TZID=Europe/Paris:20250612T111500 DTSTAMP:20250523T091324Z CREATED:20250407T123707Z LAST-MODIFIED:20250523T091324Z UID:49045-1749723300-1749726900@www.bricbordeaux.com SUMMARY:Invited seminar - Romain PARENT - 12-06-2025 DESCRIPTION:Invited seminar by team 6 MIRCADE (Methods and Innovations for the Research in Pediatric Cancers.) headed by Christophe Grosset. \nRomain PARENT\nHepatitis Viruses & Liver Pathogenesis (PathLiv) Laboratory – UMR 1350\nInserm – Claude Bernard Lyon 1 University – Lyon Hepatology Institute \nThe interest of liver innervation in chronic liver disease and liver cancer. \nAbstract\nHepatocellular carcinoma (HCC) care has long been hampered by the enigmatic nature of disease onset across patients\, evolution\, as well as of response or resistance to treatment. Hepatic neural cells are likely the least studied liver cell type and mediate patients singularities from the ANS to the organ in real-time. These cells\, belonging to the autonomic nervous system (ANS)\, mediate liver/whole body crosstalk. Pathological innervation of the ANS has been identified in cancer\, nurturing tumor stroma and conferring stronger carcinogenic properties.\nIn this presentation focusing on a pathogenic continuum between normal liver and HCC\, we will present evidence for: (i) deep alterations of neural markers along this spectrum\, (ii) the presence of neural pools of cells in lesions\, (iii) the introduction of a novel neuronal score-based approach for stratification with respect to pathological and immunological considerations\, and (iv) functional studies causally demonstrating the interest of these notions for rational and accessible therapeutic intervention. \n  \nBiography\nI obtained a PharmD at the U. of Aix-Marseille 1 in 2001 and a PhD in hepatic virology in 2004 through a PhD exchange program between the Center for the Study of Hepatitis C at the Rockefeller University of New-York and the Inserm Unit 271 in Lyon\, working on the early HCV tissue culture systems.\nI then spent four years at the Fred Hutchinson Cancer Research Center in Seattle working on HCV virology and cell translation. I obtained an Inserm CR2 position in 2009.\nI have been till then leading an independent group within Fabien Zoulim’s PathLiv laboratory\, gradually evolving from translational virology towards the study of liver innervation in pathology\, through a long term work on the axonal guidance cue netrin-1.\nMy group’s work on netrin-1 have ended up in the Phase III HCC-NET1 clinical trial which has for goal to target the axonal guidance factor netrin-1 in HCC. I recently obtained a Master degree in philosophy. As a teaching unit head at the Oncology Master of Lyon 1\, I also tackle these issues through the mind-body philosophical paradigm with the students. \n  URL:https://www.bricbordeaux.com/en/event/invited-seminar-romain-parent-12-06-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/04/invited-seminar-romain-parent-2025-06-12.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250617T120000 DTEND;TZID=Europe/Paris:20250617T130000 DTSTAMP:20250602T131305Z CREATED:20250602T131305Z LAST-MODIFIED:20250602T131305Z UID:49520-1750161600-1750165200@www.bricbordeaux.com SUMMARY:Webinar “L’Heure Heka”: How Can You Tell If Research Results Have Innovation Potential? DESCRIPTION:L’Heure Heka is a webinar series dedicated to the intersection of research\, innovation\, and impact. It is organized by SATT Aquitaine Science Transfert as part of the Pôles Universitaires d’Innovation (University Innovation Clusters): Bordeaux\, Sud-Aquitaine Innovation\, and Open Campus Innov. \n________________________________________________________________________ \nThe BRIC is in the spotlight for this 8th edition of L’Heure Heka. \nWhat are the early indicators that suggest a project has strong valorization potential?\nWhat obstacles do researchers face?\nWhat do researchers expect from early-stage support? \nOn Tuesday\, June 17\, 2025\, join us for a discussion on the valorization of research\, using the BRIC as a case study. But this isn’t just about healthcare!\nTogether with Grégoire PREVOST\, CEO of CIPREVO\, and Frédéric SALTEL\, Director of the BRIC\, we’ll explore the levers that help translate innovation from the lab into real-world impact. \nGrégoire PREVOST will share his insights from his experience as a “PUI Entrepreneur-in-Residence\,” a role he held for six months within the BRIC to raise awareness\, structure\, and support high-potential research projects. \nFrédéric SALTEL will provide his perspective as Director of the BRIC on the challenges and opportunities of such an approach. \n\nRegister here: https://blog.ast-innovations.com/fr/heure-heka URL:https://www.bricbordeaux.com/en/event/webinar-lheure-heka-how-can-you-tell-if-research-results-have-innovation-potential/ CATEGORIES:Meetings ATTACH;FMTTYPE=image/webp:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/heure-heka-8-1.webp END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250630T110000 DTEND;TZID=Europe/Paris:20250630T120000 DTSTAMP:20250617T140511Z CREATED:20250617T140511Z LAST-MODIFIED:20250617T140511Z UID:49572-1751281200-1751284800@www.bricbordeaux.com SUMMARY:Invited seminar - Jean-François Côté - 30-06-2025 DESCRIPTION:BRIC Team 3\, Liver Cancers and Tumor Invasion\, co-directed by Violaine Moreau and Frederic Saltel\, is pleased to invite Jean-François Côté\, President and Scientific Director of the Institut de recherches cliniques de Montréal (IRCM)\, Canada\, to present a seminar open to the scientific community.\nJean-François Côté is co-supervisor of Mélissa Correia De Oliveira‘s thesis\, team 3 BRIC. \n\nTitle : Mechanistic Insights into Tumour Growth\, Metastasis\, and Dormancy in Cancer Progression.\n\n\nAbstract\n\nMetastasis is the primary cause of cancer-related deaths\, yet the biological processes that enable tumor cells to spread\, survive in distant organs\, and eventually form secondary tumors remain incompletely understood. Gaining insight into these mechanisms is essential for developing strategies to prevent and treat metastatic disease across cancer types. \nIn the first part of my presentation\, I will discuss tumour dormancy in breast cancer. To uncover regulators of dormancy\, genome-wide CRISPR screens were performed on two breast cancer cell lines: 4T1 (short dormancy) and 4T07 (prolonged dormancy). 4T07 cells uniquely depended on class III PI3K (PIK3C3) and showed elevated mTORC1 activity via peripheral lysosome signaling. Inhibiting PIK3C3 suppressed this activity in both mouse and human models\, reduced metastasis in 4T07\, and eliminated dormant cells in a HER2-driven model. These results highlight PIK3C3-mTORC1 signaling as a potential therapeutic target to prevent metastatic relapse. In the second part of the presentation\, I will focus on RAS family proteins that regulates key signaling pathways involved in cell growth\, differentiation\, and survival. While canonical RAS proteins are well studied\, the broader group of 35 human RAS-related GTPases remains largely unexplored. Using proximity-dependent biotinylation (BioID) in three cell models\, we mapped interaction networks and subcellular localizations across the family. This generated a high-confidence interactome\, revealing thousands of spatially resolved associations. By analyzing nucleotide-state-specific variants\, we identified context-dependent interactions with effectors and regulators. Comparative clustering highlighted conserved and unique features across subfamilies. Integration with DepMap data uncovered essential crosstalk with regulators Rho GTPases and cytoskeletal dynamics in canonical RAS proteins. This resource advances our understanding of RAS-family signaling and its roles in development\, disease\, and cancer. \n\n\n📆 Monday\, June 30\, 2025\, 11 a.m.\n📌 Conference room BBS (Bordeaux\, Biologie\, Santé)\,\n2 rue dr Hoffmann Martinot\, Bordeaux. Université de Bordeaux\, site Carreire URL:https://www.bricbordeaux.com/en/event/invited-seminar-jean-francois-cote-30-06-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/jean-francois-cote-2025-06-30.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250702T100000 DTEND;TZID=Europe/Paris:20250702T130000 DTSTAMP:20250627T075338Z CREATED:20250602T095142Z LAST-MODIFIED:20250627T075338Z UID:49523-1751450400-1751461200@www.bricbordeaux.com SUMMARY:HDR Defense – Thomas MATHIVET DESCRIPTION:HDR Defense (Accreditation to Supervise Research) in Life and Health Sciences \nThomas Mathivet Team 01 – Tumor and Vascular Biology Laboratory \n“Les molécules de guidage : de l’angiogenèse à la dynamique stromale et à l’invasion des tumeurs cérébrales” \nWednesday\, July 2\, 2025 at 10:00 AM \nBBS Amphitheater\, 2 rue Dr H. Martinot\, Bordeaux (Carreire Campus) \nJury \n➢ M Eric CHEVET\, Directeur de recherche\, Biosit\, INSERM – Rapporteur\n➢ Mme Barbara GARMY-SUSINI\, Directrice de recherche\, I2MC\, INSERM – Rapporteure\n➢ Mme Anna-Rita CANTELMO\, Chargée de recherche\, Université de Lille – Rapporteure\n➢ M François MOISAN\, Docteur\, Université de Bordeaux – Examinateur\n➢ M Andreas BIKALVI\, Professeur des universités\, Université de Bordeaux – Examinateur URL:https://www.bricbordeaux.com/en/event/hdr-defense-thomas-mathivet/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/soutenance-hdr-thomas-mathivet-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250704T110000 DTEND;TZID=Europe/Paris:20250704T120000 DTSTAMP:20250522T081608Z CREATED:20250522T081608Z LAST-MODIFIED:20250522T081608Z UID:49391-1751626800-1751630400@www.bricbordeaux.com SUMMARY:Invited seminar - Adriano Sabino - 04-07-2025 DESCRIPTION:Pr Adriano Sabino is invited by Vanessa Desplat\, Team 10\, Normal and Leukemic Hematopoietic Stem Cells. \nTitle: Omics Sciences Applied to the Investigation of Potential Biomarkers and Therapeutic Targets in Acute Leukemias \nPresenter: Prof. Adriano de Paula Sabino – Federal University of Minas Gerais (UFMG)\, Brazil \nBio: Associate Professor at the Federal University of Minas Gerais (UFMG)\, Brazil. Holds a Ph.D. in Pharmaceutical Sciences with postdoctoral training in cancer therapy resistance at Michigan State University. Academic and research expertise in Clinical\, Experimental\, and Molecular Hematology. Research interests encompass cancer biology\, acute and chronic leukemias\, chemotherapy resistance\, molecular and cellular biomarkers\, functional genomics\, proteomics\, metabolomics\, nanobiomaterials\, regenerative medicine\, cell-based therapies\, and the application of bioinformatics to precision medicine. \nAbstract: \nAcute leukemias\, including Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)\, are aggressive hematologic malignancies with high biological heterogeneity and limited predictive tools for therapeutic response and disease progression. In this context\, omics sciences offer powerful strategies to unravel the molecular complexity underlying these diseases and support the identification of new biomarkers and therapeutic targets. \nThis seminar will provide an overview of our translational research efforts combining metabolomics\, clinical peptidomics\, and machine learning. We will discuss the conceptual and methodological foundations for applying mass spectrometry-based omics approaches (LC-MS and MALDI-TOF/MS) to plasma samples\, as well as the integration of artificial intelligence algorithms to enhance biomarker discovery\, risk stratification\, and individualized therapeutic guidance. \nAdditionally\, we present the rationale and design of predictive modeling studies employing clinical and genomic datasets from AML patients. These models\, based on supervised learning techniques\, aim to improve the accuracy of outcome prediction and inform precision oncology strategies. \nOur interdisciplinary approach highlights the potential of integrating systems biology\, data science\, and clinical research to advance personalized medicine in oncohematology. \nKeywords: Acute leukemia\, ALL\, AML\, biomarkers\, omics sciences\, LC-MS\, MALDI-TOF/MS\, machine learning\, precision oncology\, clinical stratification. \n📆 Friday 04-07\, 11am \n📌 BBS conference room\, 2 rue Dr Hoffmann Martinot Bordeaux URL:https://www.bricbordeaux.com/en/event/invited-seminar-adriano-sabino-04-07-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/seminar-adriano-sabino-2025-07-13.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20250708 DTEND;VALUE=DATE:20250712 DTSTAMP:20250605T085034Z CREATED:20250605T085034Z LAST-MODIFIED:20250605T085034Z UID:49524-1751932800-1752278399@www.bricbordeaux.com SUMMARY:JOBIM 2025 – Open Days in Biology\, Informatics\, and Mathematics DESCRIPTION:From July 8 to 11\, 2025\, Bordeaux will host the 2025 edition of JOBIM (Journées Ouvertes en Biologie\, Informatique et Mathématiques) — a major event for the French-speaking bioinformatics community. This year’s conference will take place at LaBRI (Bordeaux Computer Science Research Laboratory)\, bringing together researchers\, engineers\, PhD students\, and professionals from both digital and life sciences to explore the latest developments in the field. \nThrough the ODIL unit (Omics Data Integration & visuaLization)\, BRIC’s internal bioinformatics cell\, two of our members are currently part of the event’s organizing committee: \n\nCyril Dourthe\, bioinformatics research engineer (BRIC and OncoProt platform)\nÉlodie Darbo\, research engineer in Team 7 – Targeting Transcription in Breast Cancer\n\nTheir involvement reflects the growing role of bioinformatics in oncology research\, particularly in the work carried out within our laboratory\, where the analysis of large-scale data from RNA-seq\, epigenomics\, and cell modeling has become an essential foundation. \nHeld at the crossroads of biology\, mathematics\, and computer science\, the JOBIM conference offers a rich program of talks\, workshops\, roundtables\, and networking opportunities. The 2025 edition promises excellent visibility for research conducted in our region and for all stakeholders driving innovation in health. \n\nProgram & registration: https://jobim2025.labri.fr\n\nRegistration open from May 15 to June 15\, 2025 URL:https://www.bricbordeaux.com/en/event/jobim-2025-open-days-in-biology-informatics-and-mathematics/ LOCATION:LaBRI CATEGORIES:Meetings ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/gclv2l9wiaaw6oe-scaled.jpeg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20250901 DTEND;VALUE=DATE:20251001 DTSTAMP:20250814T125719Z CREATED:20250814T124605Z LAST-MODIFIED:20250814T125719Z UID:49882-1756684800-1759276799@www.bricbordeaux.com SUMMARY:Gynecological Cancer Awareness Month - Turquoise September DESCRIPTION:As part of Septembre Turquoise\, Gynecological Cancer Awareness Month\, members of the 2.2 Oncology\, Gynecology\, and Proteostasis (OncoGyne) team led by Frederic Delom are participating in events organized by the Bergonié Institute. \n📅 From Monday\, September 1 to Tuesday\, September 30.\nProgram offered by the IMAGYN association\, a meeting and information space with the involvement of professionals from the Bergonié Institute. \n  \nProgram \n  \nMore information to come URL:https://www.bricbordeaux.com/en/event/gynecological-cancer-awareness-month-turquoise-september/ LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France CATEGORIES:Meetings ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/08/septembre-turquoise-bergonie-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250909T110000 DTEND;TZID=Europe/Paris:20250909T120000 DTSTAMP:20250711T151927Z CREATED:20250711T151927Z LAST-MODIFIED:20250711T151927Z UID:49733-1757415600-1757419200@www.bricbordeaux.com SUMMARY:Invited seminar Gautier Follain - 09-09-2025 DESCRIPTION:The BRIC unit welcomes Gautier Follain for a seminar open to the scientific community. \n  \nGautier Follain\, PhD \nShared postdoctoral researcher between the laboratories of Pr. Johanna Ivaska (University of Turku) Dr. Guillaume Jacquemet (Åbo akademi)\, both located in Turku (Finland). \nDocent at the University of Turku\, Field of application: Biophysics of cancer. \n  \nDissecting the intravascular adhesion and extravasation of Pancreatic Ductal AdenoCarcinoma. \n📆 Tuesday\, September 9 11 a.m. \n📌 BBS conference room\, 2 rue Dr Hoffmann Martinot\, Bordeaux \n  \nAbstract. \nSolid tumor progression is a complex succession of events happening in different spaces and times in the body\, ultimately leading to the formation of life-threatening metastases. To colonize distant organs\, cancer cells are exploiting the circulatory networks as natural paths before stopping in small vessels and crossing the endothelial barrier. \nMy current research focuses on the steps of intravascular adhesion and extravasation (crossing of the vessel border) of pancreatic ductal adenocarcinoma (PDAC) cell lines. My main objectives are to decipher the mechanisms allowing the cells to break the endothelial barrier\, in an attempt to identify key factors and actors during the process. I work with microfluidic models to better reproduce the physiologic conditions of perfused vessels\, zebrafish embryos which are transparent and very rapidly develop a complex vascular system and murine models. All three are coupled with quantitative and high-resolution live imaging and to single cell characterization approaches (scRNAseq\,mass cytometry\,…). \nMy ongoing results support the idea that heterogeneity of cancer\, even among laboratory cell lines\, is driving different adhesion/extravasation routes that are dramatically understudied. My talk will give an overview of my postdoc projects. 1. FlowVision\, our deep-learning based image analysis framework\, allowing the dissection of the arrest to stabilisation of circulating PDAC and immune cells (Follain et al. BioRxiv 2024). 2. An unbiased enrichment-based screening for key actors of the intravascular adhesion step. 3. The discovery of a novel extravasation route used by PDAC cells. \n  \nBio. \nI did a PhD in life science in the lab. of Dr. Jacky Goetz (Strasbourg). I studied the role of blood flow forces on arrest\, adhesion and extravasation of circulating breast/mammary cells\, using multiple imaging modalities\, mostly applied to microfluidics and zebrafish embryos. I described endothelial remodeling around arrested tumor cells as an extravasation mechanism of cancer cells (Follain et al. Dev cell 2018). Our works demonstrated that not only size exclusion but also shear forces are biophysic parameters driving the metastatic spreading (Follain et al. NRC 2020).\nI moved to Turku as a shared postdoc between the well established Cell adhesion lab of J. Ivaska\, expert in integrin biology\, and the newly born lab of G. Jacquemet focusing on cellular protrusion and cell migration. I used similar models to study the metastatic cascade of pancreatic ductal adenocarcinoma. I added to my skill set deep-learning based image analysis (Follain et al. BioRxiv 2024)\, imaging techniques\, murine models and more. \nI am now looking for the next step of my career in France..! URL:https://www.bricbordeaux.com/en/event/invited-seminar-gautier-follain-09-09-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/07/gautier-follain-2025-09-09.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250918T080000 DTEND;TZID=Europe/Paris:20250918T120000 DTSTAMP:20250811T161757Z CREATED:20250731T100014Z LAST-MODIFIED:20250811T161757Z UID:49856-1758182400-1758196800@www.bricbordeaux.com SUMMARY:SBM Department Scientific Platforms Exhibition DESCRIPTION:The SBM Department invites you to a special half-day event on Thursday\, September 18\, from 9 a.m. to 12 p.m.\, dedicated to scientific and technical platforms. This half-day event aims to raise awareness of the platforms’ activities and promote exchanges between doctoral students\, ITA/BIATSS\, scientists\, and any other interested staff. \nThe Platform exhibition will take place on the forecourt and/or in the lobby of the BBS (2 rue du Dr Hoffmann Martinot\, Bordeaux)\, depending on weather conditions. The programme includes : \n\nStands hosted by platform managers\nInteractive discussions and presentations\nA snack to share a convivial moment\n\nHow to participate? \n\nVisitors can simply come and explore the various stands at their own pace.\n\nFind all 18 platforms at this link. \n👉 Among them\, here are the platforms with a particular link to our BRIC unit: \n\nAquiDerm\nAquiDerm is the technology transfer structure of the team 05 – Translational Research In Oncodermatology and Orphan skin diseases (TRIO2)\, led by Hamid-Reza Rezvani and Marie Beylot-Barry\nOne of the platform’s scientific managers is Hamid-Reza Rezvani – with Julien Seneschal(ImmunoConcEpT)\, the co-managers are Jérôme Rambert and Muriel Cario\, and the scientific expert is Alain Taieb.\nIt is administratively attached to ADERA.\nCellOxia\nThe CellOxia hypoxia culture platform was created by Team 10 – Normal and Leukemic Hematopoietic Stem Cells\, led by Jean-Max Pasquet.\nThe scientific manager of the platform is Jean-Max Pasquet. The technical manager of the platform is Arnaud Villacreces.\nCrisp’edit\nThe CRISP’edit platform was created by Team 11 – Modeling Mechanisms of Transformation and Resistance in Leukemia\, led by Catherine Sawai.\nThe scientific manager of the core facility is Béatrice Turcq The technical manager of the platform is Valérie Prouzet-Mauleon.\nHistopath\nThe Histopathology core facility was created by Team 03 – Liver Cancers and Tumor Invasion\, led by Violaine Moreau and Frederic Saltel. Pierre Dubus (team 4)\, Brigitte Le bail (team 3)\, and Béatrice Turcq (team 11) are members of the Scientific Committee The technical manager of the core facility is Nathalie Dugot-Senant.\nOncoProt\nThe proteomic analysis core facility\, OncoProt\, was created by Team 03 – Liver Cancers and Tumor Invasion\, led by Violaine Moreau and Frederic Saltel\nThe scientific manager of the platform is Frederic Saltel\, and the technical manager is Anne-Aurélie Raymond.\nVect’UB\nThe vectorology platform\, Vect’UB\, was created by Team 08 – Genetic Biotherapies and Oncology (BioGO)\, led by Sandrine Dabernat and François Moreau-Gaudry. The scientific manager of the platform is François Moreau-Gaudry.\nThe technical manager of the platform is Véronique Guyonnet-Dupérat.\nVivOptic\nThe Vivoptic platform was created by the IMOTION team\, which joined Team 04 – Digestive cancers associated with Helicobacter infection\, cancer stem cells\, and therapeutic strategies\, led by Christine Varon. Christine Varon is a member of the scientific committee. The technical manager is Coralie Genevois.\nXenofish\nThe Xenofish platform was created by team 02 – Reprogramming of tumor activity and the associated microenvironment (Rytme)\, headed by A. Majid Khatib. The scientific manager of the platform is Géraldine Siegfried. The technical managers are Sandrine Fedou and Élodie Muzotte. The zootechnicians are Isabelle Auguste and Wendy Comandatore.\n\n  URL:https://www.bricbordeaux.com/en/event/sbm-department-scientific-platforms-exhibition/ LOCATION:accueil Bâtiment BBS – Bordeaux Bioloie Santé\, 2 rue du Dr Hoffmann Martinot\, Bordeaux\, France CATEGORIES:Meetings ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/07/banniere-salonplateformes-37888b48d43df7f650a6adeac73e407e.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20250922 DTEND;VALUE=DATE:20251011 DTSTAMP:20250918T160613Z CREATED:20250522T104742Z LAST-MODIFIED:20250918T160613Z UID:49403-1758499200-1760140799@www.bricbordeaux.com SUMMARY:Cancer Neuroscience School - Bordeaux - 09/22 to 10/02 DESCRIPTION:Antonio C. Pagano Zottola\, Junior Professor Team 1 – Tumor and Vascular Biology Laboratory of our unit is co-organizing a Cancer Neuroscience School in Bordeaux from September 22 to October 10\, 2025. with Anna Golebiewska\, Luxembourg Institute of Health et Varun Venkataramani\, German Cancer Research Center. \n  \nThis 3-week training course is aimed at scientists at Master 2 level and above. \n  \nProgram of seminars open to the scientific community\n  \nThe Bordeaux Neuroscience School is part of Bordeaux Neurocampus\, the neuroscience department of the University of Bordeaux. The school operates on the principle that training in neuroscience and oncology research involves hands-on experimentation in a real research laboratory. A number of renowned speakers in neuro-oncology will be taking part in the course. \nWhat to expect? \n\nHands-on projects using cutting-edge technologies from neuroscience and oncology\,\nLectures by top scientists and a Brain Prize 2025 : Frank Winkler\,\nTechniques ranging from primary cultures and organoids to advanced imaging\,\nA collaborative\, interdisciplinary environment to boost your research skills.\n\n  \nFull details and registration \n  \nDeadline Extended: Apply by July 7th URL:https://www.bricbordeaux.com/en/event/cancer-neuroscience-school-bordeaux-09-22-to-10-02/ CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/05/cajal-school-cancer-neuroscience-2025-0910-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250923T133000 DTEND;TZID=Europe/Paris:20250923T170000 DTSTAMP:20250918T145053Z CREATED:20250918T143354Z LAST-MODIFIED:20250918T145053Z UID:50017-1758634200-1758646800@www.bricbordeaux.com SUMMARY:Thesis defense by Ruxue JIA DESCRIPTION:Ruxue JIA will publicly defend her doctoral thesis in Cancer Biology\, supervised by Armelle MENARD\, Team 4: Digestive cancers associated with Helicobacter infection\, cancer stem cells\, and therapeutic strategies. \nTitle : Etude des voies de signalisation cellulaire modulées par les génotoxines bactériennes \nDefense scheduled for Tuesday\, September 23\, 2025\, at 1:30 p.m.\nAmphi 7\, Université de Bordeaux\, Campus Carreire\, 146 rue Leo Saignat 33000 Bordeaux \nNotice of defense with abstract available at this link (error in the notice) URL:https://www.bricbordeaux.com/en/event/thesis-defense-by-ruxue-jia/ LOCATION:salles Nord et Sud – RDC Bâtimenet Bordeaux Biologie Santé (BBS)\, 2 rue du Dr Hoffmann Martinot\, Bordeaux\, France CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/soutenance-de-these-ruxue-jia-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250924T140000 DTEND;TZID=Europe/Paris:20250924T170000 DTSTAMP:20250918T151552Z CREATED:20250918T151552Z LAST-MODIFIED:20250918T151552Z UID:50028-1758722400-1758733200@www.bricbordeaux.com SUMMARY:HDR thesis defense by Delphine Fessart DESCRIPTION:Delphine Fessart\, team 2.2 Oncology & Gynecology Laboratory (OncoGyne)\, will defend her Habilitation à Diriger des Recherches (HDR) on Wednesday\, September 24\, at 2:00 p.m.\, in the Conference Room (R+7) of the Bergonié Institute. \nTitle : « Décrypter les mécanismes moléculaires conduisant au développement tumoral ». URL:https://www.bricbordeaux.com/en/event/hdr-thesis-defense-by-delphine-fessart/ LOCATION:Institut Bergonié\, 229 Cours de l'Argonne\, Bordeaux\, 33076\, France CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/soutenance-hdr-delphine-fessart.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20250925 DTEND;VALUE=DATE:20250927 DTSTAMP:20250602T104611Z CREATED:20250602T104611Z LAST-MODIFIED:20250602T104611Z UID:49525-1758758400-1758931199@www.bricbordeaux.com SUMMARY:Symposium “Microenvironment and Immunotherapy of Sarcomas” DESCRIPTION:The BRIC is pleased to share the announcement of the 3rd International Symposium on Sarcomas\, organized as part of the RHU CONDOR program\, to be held on September 25–26\, 2025\, in Bordeaux. \nThis year’s symposium\, titled “Microenvironment and Immunotherapy of Sarcomas”\, will bring together international researchers\, clinicians\, and experts to address key challenges in the study of connective tissue tumors. Special focus will be placed on immunotherapy and the tumor microenvironment — two central pillars of current therapeutic strategies. \nThe event is organized by the CONDOR program\, a national Hospital-University Research (RHU) project led by Antoine Italiano\, oncology researcher\, clinical oncologist\, and head of Team 9 “SarcoTarget” at the BRIC. His team\, in collaboration with Institut Bergonié\, specializes in developing new therapeutic approaches for sarcomas\, which are rare and complex cancers. \nThis symposium will be a unique opportunity to highlight the latest scientific breakthroughs and strengthen collaboration within the global sarcoma research community. \n\n\nRegistration deadline: September 11\, 2025 \n\n\nRegistration and full program: https://condorprogram.com/symposium-3rd-edition \n\n\n\n\nWe strongly encourage you to register early to take part in these two days of rich scientific and clinical exchange. URL:https://www.bricbordeaux.com/en/event/symposium-microenvironment-and-immunotherapy-of-sarcomas/ LOCATION:Agora du Haut Carré – Université de Bordeaux\, 43 rue Pierre Noailles\, Talence\, France CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/design-sans-titre.jpg ORGANIZER;CN="RHU Condor":MAILTO:contact@condorprogram.com END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250929T140000 DTEND;TZID=Europe/Paris:20250929T170000 DTSTAMP:20250918T132717Z CREATED:20250808T100416Z LAST-MODIFIED:20250918T132717Z UID:49855-1759154400-1759165200@www.bricbordeaux.com SUMMARY:Thesis defense by Florian ROBERT DESCRIPTION:Thesis defense in computer science \nFlorian ROBERT\, team 06 – MIRCADE\, Methods and Innovations for the Research in Pediatric Cancers. \nCo-supervision of thesis: Christophe Grosset (BRIC) and Baudouin Denis de Senneville (IMB- Institut des Mathématiques de Bordeaux) \nMonday\, September 29\, 2 p.m. \n“Exploration de l’organisation interne des tissus tumoraux par imagerie volumétrique\, méthodes numériques et apprentissage profond.” \nSalle des Actes bâtiment A33 campus Sciences et Technologies à Talence \nAbstract: \nUnderstanding the internal organization of tumor tissues is essential for improving cancer treatment in children. This thesis focuses on hepatoblastoma\, the most common malignant liver tumor in children. Based on 3D electron microscopy images\, a digital twin of the tumor tissue was created using innovative tools to automatically segment and identify biological structures such as cells\, nuclei or blood capillaries. This information was then used to analyze the internal organization of the tissue using unsupervised learning methods. This work opens the way to a better understanding of tumor architecture\, and ultimately aims to improve diagnosis\, choose the best treatment and better care for children with cancer. \n  \nJury members: \nMs Karin PERNET GALLAY\, Research Engineer\, University of Grenoble Alpes\, Rapporteur\nM. Charles KERVRANN\, Directeur de Recherche\, Université de Rennes\, Rapporteur\nMrs. Nataliya SOKOLOVSKA\, Professor\, Sorbonne University\, Examiner\nMs Christèle ETCHEGARAY\, Research Fellow\, University of Bordeaux\, Examiner\nM. Baudouin DENIS DE SENNEVILLE\, Directeur de Recherche\, Université de Bordeaux\, Directeur\nM. Christophe F. GROSSET\, Directeur de Recherche\, Université de Bordeaux\, Co-Directeur URL:https://www.bricbordeaux.com/en/event/thesis-defense-by-florian-robert/ LOCATION:salle des Actes bâtiment A33 campus Sciences et Technologies\, Talence CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/08/soutenance-de-these-florian-robert.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20251002 DTEND;VALUE=DATE:20251003 DTSTAMP:20250929T095807Z CREATED:20250618T071507Z LAST-MODIFIED:20250929T095807Z UID:49605-1759363200-1759449599@www.bricbordeaux.com SUMMARY:BRIC'Innov 2025 DESCRIPTION:BRIC’Innov \nBRIC Oncology Innovation Day \nThursday\, October 02\, 2025 \n\nBordeaux Biologie Santé (BBS) building\, \nCampus Carreire\, 2 rue Dr Hoffmann Martinot\, Bordeaux \n\n \n\n\n\nL’Institut de Recherche en Oncologie de Bordeaux (BRIC) is organizing\,\ntogether with its innovation partners\,\nthe first day dedicated to companies \nProgram to downloadVICTIM OF ITS OWN SUCCESS \nREGISTRATION IS NOW CLOSED!\nIf you are already registered\, you can still access your account by logging in. \n\n\n\n\nRegistration\n(free but mandatory) PROGRAM \n\n  \n\nFrom 8:30 a.m.: Welcome coffee and pastries \n\n\n 9 a.m. – 1 p.m.: Plenary lectures \n\n9:00 a.m.: Opening speech: Oncology\, Research\, and Innovation in the Nouvelle-Aquitaine Region\nEtienne Duguet\, Vice President of Innovation\, University of Bordeaux;\nRichard Salives\, Regional Delegate\, Inserm;\nPhilippe Nauche\, Vice President in charge of Health and the Silver Economy\, Nouvelle-Aquitaine Region;\nEric Papon or his representative\, Regional Academic Delegate for Research and Innovation.\n\n  \n\n9:30 a.m.: Presentation of the Bordeaux Institute of Oncology\nModerator: Charlotte Cosin\, Head of Innovation\, University of Bordeaux.✔ A multidisciplinary laboratory. Frédéric Saltel\, Director of BRIC\n✔ A translational research laboratory.\nChristelle Liard\, PhD\, Head of translational cancer researchat Bordeaux University Hospital;\nMonica Arnedos\, Specialist practitioner at CLCC\, Bergonié Institute \n\n\n10:20 am : Innovatives technologies to accelerate oncology research\nModerator : David Boucard\, Director\, ALLIS-NA.\n✔ Presentation of TBMCore technology platforms : Béatrice Turcq\, Director\n✔ I.Care Bordeaux program : Jean-Christophe Bernhard\, Coordinator. \n\n  \nBREAK (11:00 a.m. – 11:20 a.m.) \n  \n\n11:20 a.m.: BRIC projects and innovation dynamics\nModerator : Lorena Delgado-Zabalza\, Head of Health Innovation\, University of Bordeaux..\n✔ Cible Slit2 project : Enhancing immunotherapies in the treatment of brain cancers. Thomas Mathivet\, CR\, Team 1 BRIC\n✔ Revalis Project: Convertases and protein maturation for new therapies in immuno-oncology\, A. Majid Khatib\, PhD\, Team 2 BRIC\n✔ CRISPR-Cas patent: From diagnosis to gene therapy. Sandrine Dabernat\, PU-PH & Aurélie Bedel\, PU-PH\, Team 8 (BioGO) BRIC\n \n\n12:00 p.m.: From the laboratory to the start-up\, a collective adventure involving local innovation stakeholders\nModerator: Sophie Hervé\, Health Sector Affairs Officer\, University of Bordeaux\nHadrien Mary\, Co-founder – Beliver\nLaura Bergeon\, Business developper – SATT AST\nLucia Robert\, CEO – MATWIN\nClémence Roy\, Start-up Manager – UNITEC \nDavid Boucard\, Director – ALLIS-NA\n\n  \n  \n\n12:30 p.m.: Funding academic-private collaborations\n Moderator : Damien Louessard\, Head of Ecosystem Department\, University of Bordeaux\nMagali Pages\, Head of European Innovation\, ADI Nouvelle-Aquitaine.\nAlice Recalde\, European Projects Engineer (assembly)\, University of Bordeaux.\nMarina Galicki\, Project Manager for Innovation and Health/Chemistry/Materials – Regional Economic Department\, DREETS.\nYves Ducq\, Deputy Regional Academic Delegate for Research and Innovation.\nMarianne Lamour\, Project Manager\, Higher Education\, Research\, and Technology Transfer Department\, Nouvelle-Aquitaine Region.\nLucie Teixeira-Marinho\, Deputy Director\, Innovation\, Industry\, and Attractiveness\, Nouvelle-Aquitaine Region.\n\n\n\n  \n\n 1:00 p.m. – 2:00 p.m.: Lunch and networking \n  \n\n 2:00 p.m. – 4:00 p.m. : MEET MY PARTNER* \n \n⏳The B2B meetings are closed! Opportunity for informal meetings in dedicated areas on the day \n🔎 Need help? Contact : bric-innov-2025@sciencesconf.org \n \n\n\n\n\nPractical information \n  \n🚘Apart from the parking spaces reserved for university staff (badge required)\, you will find spaces closer by on the sidewalk along the wall on Rue du Dr Hoffmann Martinot. Otherwise\, there is a parking lot reserved for visitors a 5-minute walk away\, located at 125 Bethmann Street. \n🚊Take tram A to the Saint Augustin stop\, then follow the “cycles et piétons” (cycles and pedestrians) markings on the ground across the CHU campus. \n🚍Several bus lines nearby\, see location map \nlocation map \n\n\n\nRegistration\n(free but mandatory) \n\n#Synergies #fFinancements #SuccessStory #Networking #PlateformesTechnologiques #RencontresChercheurs\n \n\nIn partnership with:\n\nContact et informations : bric-innov-2025@sciencesconf.org \n* URL:https://www.bricbordeaux.com/en/event/bricinnov-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/affiche-bricinnov-2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251013T090000 DTEND;TZID=Europe/Paris:20251013T130000 DTSTAMP:20250925T093649Z CREATED:20250925T093649Z LAST-MODIFIED:20250925T093649Z UID:50143-1760346000-1760360400@www.bricbordeaux.com SUMMARY:Thesis defense by Chloé Redouté-Timonnier DESCRIPTION:Chloé Redouté-Timonnier\n\, team 6 MIRCADE will defend her thesis in cancer biology on Monday\, October 13\, at 9 a.m. in the lecture hall of the Bordeaux Biology Health (BBS) building at the University of Bordeaux – 2 rue du Dr Hoffmann Martinot\, Bordeaux. \nImpact des isoformes DDR1a et DDR1b sur le développement du carcinome rénal à cellules claires (ccRCC). \nThesis supervisor Patrick Auguste. \nSummary in the defense notice at this link \nJury members:\nM. Ulrich VALCOURT – Laboratoire de Biologie Tissulaire et Ingénierie Thérapeutique (LBTI) UMR 5305 CNRS et Université Claude Bernard Lyon 1\, Rapporteur\nM. Curzio RUEGG – University of Fribourg\, Switzerland\, Rapporteur\nMme Elisabeth GENOT – Bioingénierie Tissulaire (BioTis) Inserm U1026 Université Bordeaux\, Examinatrice\nM. Hamid MORJANI – BioSpectroscopie Translationnelle BioSpecT – EA7506 UFR de Pharmacie – Université deReims\, Examinateur\nMme Isabelle SAGOT – IBGC UMR 5095 – Université de Bordeaux\, Examinatrice URL:https://www.bricbordeaux.com/en/event/thesis-defense-by-chloe-redoute-timonnier/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars,Thesis defenses ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/soutenance-de-these-chloe-redoute-timonnier.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251023T103000 DTEND;TZID=Europe/Paris:20251023T113000 DTSTAMP:20250929T081714Z CREATED:20250929T081714Z LAST-MODIFIED:20250929T081714Z UID:50101-1761215400-1761219000@www.bricbordeaux.com SUMMARY:Invited seminar Thamil Selvee Ramasamy - 23-10-2025 DESCRIPTION:Thamil Selvee Ramasamy\nStem Cell Research Laboratory\, Department of Molecular Medicine\, Faculty of Medicine\, Universiti Malaya\, Kuala Lumpur\, MALAYSIA. \nInvited by Delphine Fessart and the Oncology and Gynaecology (OncoGyne) Laboratory head by Frederic Delom \nThursday\, October 23 at 10:30 a.m.\, BBS conference room\, 2 rue du Dr Hoffmann Martinot \nStem Cell Plasticity in Developmental Biology\, Regenerative Medicine and Cancer \nShort biosketch: Dr. Ramasamy earned her PhD in Clinical Medicine Research Programme (specialisation: human embryonic stem cell research) from Imperial College London\, UK. She is currently serving as an associate professor at the Department of Molecular Medicine and heading the Stem Cell Biology Laboratory at Universiti Malaya\, Malaysia. Exploring the potential of stem cells in development of therapy for degenerative diseases and targeting cancer stem cells are the primary focus of her research. More details can be found in her page: umexpert.um.edu.my/selvee.html and Web of Science Researcher IDF-3044-2012. \n\nAbstract \nStem cell plasticity is the key concept in developmental biology\, enabling the zygote and inner cell mass to give rise to all 208 specialized cell types through exquisitely precise signalling and cell–cell communication. I will share on how embryonic stem cells can be used to understand and engineer cell fates\, focusing on my work on neuronal and hepatic differentiation. Both embryonic and adult stem cells offer a versatile reservoir for generating therapeutically relevant cells in regenerative medicine\, this talk will cover the work done in our laboratory on developing regenerative therapies using stem cells in combination with other approaches. \nIntriguingly\, in oncology\, cancer stem cell plasticity fuels tumour heterogeneity\, therapy resistance\, and relapse\, presenting persistent challenges for effective treatment. In the interest of BRIC researchers\, I will devote most of my talk to how we model cancer stem cells in culture\, using these models to unravel the molecular regulation governing plasticity in malignant contexts\, with a particular focus on hepatocellular carcinoma. Since the direction of our current work aims to leverage cutting-edge technologies including spatial transcriptomics\, nanotechnology-based drug delivery\, drug repurposing\, and cancer immunotherapy to intercept cancer stem cell plasticity and advance precision oncology\, I would like explore your expertise and discuss potential collaborations with BRIC researchers in this domain. \n  \nContact to meet Thamil Selvee Ramasamy : Delphine Fessart : delphine.fessart@inserm.fr URL:https://www.bricbordeaux.com/en/event/invited-seminar-thamil-selvee-ramasamy-23-10-2025/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/09/thamil-selvee-ramasamy-2025-10-23-v2.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251113T100000 DTEND;TZID=Europe/Paris:20251113T113000 DTSTAMP:20251031T135221Z CREATED:20251031T135221Z LAST-MODIFIED:20251031T135221Z UID:50307-1763028000-1763033400@www.bricbordeaux.com SUMMARY:Graduate program Cancer Biology invited seminar - Raul V. DURAN DESCRIPTION:The lecturers and professors of the Graduate Program in Cancer Biology invite Raul V. Duran to give a lecture in Bordeaux on Thursday\, November 13\, from 10:00 a.m. to 11:30 a.m. in the conference room of the BBS building\, 2 rue du Dr Hoffmann Martinot.\nRaul Duran will be available on Wednesday\, November 12\, during the morning\, to talk with researchers who wish to meet him.\nContact: jose-eduardo.gomes@u-bordeaux.fr\n\n\nRaul V. Duran\nSpanish National Research Council (CSIC) – Séville\nGroup Leader of the Group of Metabolism and Cell Signaling\n \n“Metabolic imbalance as a therapeutic strategy in cancer.” \n  \nAbstract \nDuring last years\, a great amount of effort has been dedicated to elucidate the crosstalk between cellular metabolic and bioenergetic flows with signaling processes\, and how this interaction contributes to coordinate the growth and homeostasis of cells and tissues. Particularly\, how these interaction mechanisms are deregulated in cancer at the molecular and cellular level is a matter of intense research\, with the aim of using this knowledge to propose new therapeutic alternatives. Our research has established the processes of interaction between the metabolism of the amino acid glutamine\, the most abundant in human blood and the most important from an energetic point of view for cells\, with cell signaling via the mTOR pathway\, a protein complex essential in the regulation of cell growth and metabolism\, and autophagy. More recently\, we focused our research on metabolic adaptation associated to therapy resistance in glioblastoma (GBM)\, one of the tumor types with the poorest survival outcomes. This work resulted in the identification of FGFR1 pathway as a major regulator of the signaling and metabolic rewiring associated with temozolomide (TMZ) resistance in GBM. Hence\, we described a mechanism of resistance that operates at two major levels. First\, a p53-mediated regulation of cell cycle inducing cell cycle arrest to allow DNA repair in response to TMZ. And second\, a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Both the p53-mediated response and the metabolic adaptation are controlled by FGFR1\, as inhibition of the FGFR1 pathway completely abolishes this signaling and metabolic reprograming\, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 activity with poor prognosis in GBM patients\, and validated the treatment of TMZ in combination with FGFR1 inhibitors as an efficient strategy to induce tumor cell death in pre-clinical animal models. This data position the receptor FGFR1 as a very promising candidate for evaluation in future clinical approaches to limit the development of therapy resistance to TMZ in GBM patients. \n  \nBiosketch \nI obtained my PhD in Biochemistry at the University of Seville (Spain) in 2005 working on cellular bioenergetics. Then\, I joined the lab of Prof. Eyal Gottlieb at the Beatson Institute for Cancer Research (Glasgow\, UK) as a postdoctoral researcher to extend my expertise on broader aspects of cancer metabolism. Later\, I moved to the lab of Prof. Michael N. Hall at the Biozentrum (Switzerland) as a senior postdoc to study the de-regulation of cellular signaling during cancer. In 2013 I joined the Institut Européen de Chimie et Biologie (Pessac\, France) as a Group Leader (INSERM\, CR position)\, integrating my previous expertise to investigate the crosstalk between metabolism and cell signaling in cancer cells. In 2018 I moved my lab to the Centro Andaluz de Biología Molecular y Medicina Regenerativa – CABIMER\, upon my assignment as Senior Research Associate (Científico Titular) at CSIC. Since them\, I am the Group Leader of the Group of Metabolism and Cell Signaling\, and in the period 2019-2022 I was the Director of the Department of Dynamics and Cell Signaling at CABIMER. In the period 2020-2024 I was the Deputy Director of CABIMER. Currently\, I am a member of the Executive Committee of the CONEXION CANCER-CSIC\, and I serve as Associate Editor of the journal Cancer & Metabolism. Since January 2025 I serve as permanent evaluator (Gestor) of the Spanish Agency of Investigation (AEI)\, in the Biomedicine – Cancer commission. URL:https://www.bricbordeaux.com/en/event/graduate-program-cancer-biology-invited-seminar-raul-v-duran/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/10/seminaire-invite-graduate-schhol-cancer-raul-v-duran.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251114T140000 DTEND;TZID=Europe/Paris:20251114T150000 DTSTAMP:20250729T144312Z CREATED:20250729T144312Z LAST-MODIFIED:20250729T144312Z UID:49802-1763128800-1763132400@www.bricbordeaux.com SUMMARY:Invited seminar Etienne Brecht & Aurélie Beaufrère - 2025-11-14 DESCRIPTION:Marion Bouchecareilh et Samuel Amintas from Team 8 “Genetic Biotherapies and Oncology” (BioGO) invite two speakers from Paris Cité University\, Center for Inflammation Research\, INSERM 1149\, Sinkus Team (From micro to macro in cancer development) for this seminar open to the scientific community. \n👉 Aurélie Beaufrère \nMorphological and molecular heterogeneity of hepatocellular carcinoma. \nAbstract:\nHepatocellular carcinoma is the most common primary malignant liver tumor. This tumor is highly heterogeneous\, both morphologically\, with eight histological subtypes described\, and molecularly\, with distinct transcriptomic groups described that are linked to both genomic alterations and morphological aspects. Some of these characteristics impact both prognosis and response to treatment. \nBiography:\nCurrently an MCU-PH in the Pathology Department at Beaujon Hospital\, my hospital and research work focuses on liver pathology\, particularly liver tumors. I am developing projects on the morphological and molecular heterogeneity of primary liver tumors\, as well as multimodal artificial intelligence projects integrating pathological\, radiological\, and molecular data. \n  \n👉 Etienne Becht \nHigh-throughput single-cell quantification of 100s of proteins using conventional flow cytometry and machine learning. \nAbstract: \nTechniques enabling single-cell resolution proteomic analyses are limited in terms of the number of cells analyzed and/or the number of proteins measured. To overcome these limitations\, we have developed “Infinity Flow\,” a method for analyzing flow cytometry data in parallel using machine learning models. By enabling the pseudo-quantification of hundreds of proteins in millions of single cells\, this technique allows for in-depth mapping of the microenvironment of complex tissues. We are currently applying it to the study of liver cirrhosis and hepatocellular carcinoma. \nBiography: \nAs an engineer by training\, I completed a thesis in cancer immunology under the joint supervision of Hervé Fridman (PUPH) and Aurélien de Reyniès (bioinformatician) at the Cordeliers Research Center in Paris. There\, I developed MCP-counter\, a method for estimating the composition of the tumor microenvironment from the bulk transcriptome. I then completed two postdoctoral fellowships\, first at the Singapore Immunology Network on mass cytometry data analysis\, then in Seattle on parallelized flow cytometry data analysis. I then worked in R&D at Servier (Computational Medicine team) before joining Valérie Paradis’ laboratory at the hospital as an INSERM research fellow. My project focuses on profiling the hepatic microenvironment using parallelized flow cytometry and developing bioinformatics methods for analyzing cytometry data. \n  URL:https://www.bricbordeaux.com/en/event/invited-seminar-etienne-brecht-aurelie-beaufrere-2025-11-14/ LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux CATEGORIES:Meetings,Scientific seminars ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/07/seminaire-e-brecht-aurelie-beaufrere-2025-11-14.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20251122 DTEND;VALUE=DATE:20251123 DTSTAMP:20251124T163138Z CREATED:20251117T182019Z LAST-MODIFIED:20251124T163138Z UID:50419-1763769600-1763855999@www.bricbordeaux.com SUMMARY:Research Opens Its Doors #3 - BRIC Participation DESCRIPTION:Our BRIC Unit participates in the SBM Department Open House \nCome and meet them! \n📆Saturday\, November 22\n🕑9h15 à 12h30 and 14h à 17h\n🚩bâtiment BBS\, 2 rue Dr Hoffmann Martinot Bordeaux (plan d’accès) \n  \nAll information about this event\n  \nMeet the scientists from our unit at these tours and workshops: \nVISITS: \n“Les supers pouvoirs des cellules” : Lamia Azzi-Martin\, Clotilde Billottet\, Arnaud Jabouille\, Martina Carlotti \n“Venez découvrir votre ADN” : Christelle Dussert\, Valérie Le Morvan\, Coralie Genevois \n“Visite d’un laboratoire de recherche” : Christine Varon\, Magalie Lalanne \n“Rencontre avec un habitant de l’estomac” : Lucie Bruhl\, Astrid Ducournau\, Jessica Massière \n“Formule 1… En rouges et Blancs” : Elodie Richard\, Valérie Lagarde \n  \nPOSTERS \nLaurence Bresson-Bepoldin et Sandrine Fedou \n  \nWORKSHOPS \nAtelier microscopie : Vanessa Desplat\, Lucie Brisson \nAtelier “Les métiers de la Recherche” : Isabelle Vigon\, Lucie Brisson \nAtelier “Les ciseaux de l’ADN” : Valérie Prouzet\, Béatrice Turcq \nAtelier “Un poisson nommé Danio” : Géraldine Siegfried\, Elodie Muzotte\, Sandrine Fedou \nAtelier pour les enfants : Lisa Renaudet-Keller \n  \nWelcome/Departure group \nLaurence Bresson Bepoldin\, Céline Léon\, Grégoire Manaud\, Lindita Lari\, Blandine Vignau\, Anne Berger\, Ana Sofia Uriola Vasquez\, Rémi Darracq\, Amandine Rousselle\, Anne Lhuillery\, Clara Jollet\, Lucie Gouret\, Melissa Correia de Oliveira\, Nina Choublier \n  \n👏Bravo à tous pour votre participation à cette journée ouverte à tous ! URL:https://www.bricbordeaux.com/en/event/research-opens-its-doors-3-bric-participation/ LOCATION:Accueil bâtiment Bordeaux Biologie Santé (BBS)\, 2 rue Dr Hoffmann Martinot\, Bordeaux\, France CATEGORIES:Meetings ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/11/vignette-jpo-departement-sbm-22-11-2025.jpg END:VEVENT END:VCALENDAR